Laboratory/Clinical Translational Research
The Prognostic Relevance of Fascin Expression in Human Gastric CarcinomaHashimoto Y. · Shimada Y. · Kawamura J. · Yamasaki S. · Imamura M.
Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: Fascin, an actin-bundling protein that is found in membrane ruffles, microspikes, and stress fibers, induces membrane protrusions and increases cell motility in various transformed cells. The expression of fascin in epithelial neoplasms has been described only recently, and its role in gastric cancer is still unknown. Methods: Paraffin sections of gastric carcinoma from 214 patients were immunohistochemically investigated using monoclonal antifascin antibody. Staining more than 5% of tumor cells was recorded as positive immunoreactivity. Results: Overall, fascin immunoreactivity was detected in 54 out of a total of 214 patients (25%). 26 patients were classified as 1+ (5–25% immunoreactive tumor cells) and 28 were 2+ (>25%). In these patients, 7 tumors showed high (>75%) fascin immunoreactivity. Increased immunoreactivity of fascin was sometimes seen at the edge of the tumor. Fascin immunoreactivity was increased according to the extent of primary tumor (p = 0.026). Fascin expression was correlated with age (p = 0.005), serosal invasion (p = 0.013), positive lymph node metastasis (p = 0.006), histopathological grading (p = 0.019), TNM stage (p = 0.003) and recurrence (p = 0.006); however, it was not correlated with distant metastasis (p = 0.108), Lauren’s type (p = 0.205), or R classification (p = 0.056). Among 166 patients with T1, T2, T3 or T4, those with fascin-positive tumors had a significantly poorer prognosis than those with fascin-negative tumors (p = 0.029). Multivariate analysis showed that fascin expression was not an independent poor prognostic factor. Conclusion: Our findings suggest that the immunohistochemical detection of fascin could provide useful information as one of the prognostic factors in gastric cancer patients.
© 2004 S. Karger AG, Basel
Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the ‘different disease’ hypothesis. Cancer 2000;88:921–932.
- Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA: Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368–1383.
- Partin AW, Schoeniger JS, Mohler JL, Coffey DS: Fourier analysis of cell motility: Correlation of motility with metastatic potential. Proc Natl Acad Sci USA 1989;86:1254–1258.
- Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001;411:375–379.
- Otto JJ: Actin-bundling proteins. Curr Opin Cell Biol 1994;6/1:105–109.
- Tilney LG, Connelly PS, Vranich KA, Shaw MK, Guild GM: Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each cross-link contribute? J Cell Biol 1998;143/1:121–133.
- Matsudaira P: Actin crosslinking proteins at the leading edge. Semin Cell Biol 1994;5/3:165–174.
- Bryan J, Kane RE: Separation and interaction of the major components of sea urchin actin gel. J Mol Biol 1978;125/2:207–224.
- Otto JJ, Kane RE, Bryan J: Formation of filopodia in coelomocytes: Localization of fascin, a 58,000 dalton actin cross-linking protein. Cell 1979;17/2:285–293.
- Bryan J: Isolation of fascin, an actin-bundling protein, and SU45, an actin-severing/capping protein from sea urchin eggs. Methods Enzymol 1986;134:13–23.
- Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC: Fascins, and their roles in cell structure and function. Bioessays 2002;24:350–361.
- Duh FM, Latif F, Weng Y, Geil L, Modi W, Stackhouse T, Matsumura F, Duan DR, Linehan WM, Lerman MI, Gnarra JR: cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein. DNA Cell Biol 1994;13:821–827.
- Yamashiro-Matsumura S, Matsumura F: Intracellular localization of the 55-kD actin-bundling protein in cultured cells: Spatial relationships with actin, alpha-actinin, tropomyosin, and fimbrin. J Cell Biol 1986;103:631–640.
- Adams JC: Cell-matrix contact structures. Cell Mol Life Sci 2001;58:371–392.
- Yamashiro S, Yamakita Y, Ono S, Matsumura F: Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell 1998;9:993–1006.
- Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF: Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 2000;18/1:83–88.
- Grothey A, Hashizume R, Sahin AA, McCrea PD: Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000;83:870–873.
- Grothey A, Hashizume R, Ji H, et al: C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 2000;19:4864–4875.
- Guvakova MA, Boettiger D, Adams JC: Induction of fascin spikes in breast cancer cells by activation of the insulin-like growth factor-I receptor. Int J Biochem Cell Biol 2002;34:685–698.
- Maitra A, Iacobuzio-Donahue C, Rahman A, et al: Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: Sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 2002;118/1:52–59.
- Jawhari AU, Buda A, Jenkins M, et al: Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 2003;162/1:69–80.
- Pelosi G, Pastorino U, Pasini F, et al: Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 2003;88:537–547.
- Goncharuk VN, Ross JS, Carlson JA: Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 2002;29:430–438.
- Japanese Gastric Cancer Association: Japanese Classification of Gastric Cancer, 2nd English Edition. Gastric Cancer 1998;1:10–24.
- Jass JR, Sobin LH, Watanabe H: The World Health Organization’s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 1990;66:2162–2167.
- Lauren P: The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma. An attempt at histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
Sobin LH, Wittekind C: TNM Classification of Malignant Tumours, ed 6. New York, Wiley, 2002.
- Wong V, Ching D, McCrea PD, Firestone GL: Glucocorticoid down-regulation of fascin protein expression is required for the steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells. J Biol Chem 1999;274:5443–5453.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.